VivoSeq
Infectious Disease

Clostridium Difficile Infection

42

Pipeline Programs↗

2

Active Trials↗

15

Companies Involved↗

Clostridium Difficile Infection is a moderately active landscape with 42 programs across 15 companies. The most active players are Johnson & Johnson, Sanofi, Novartis. 4 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 2Novartis logo

Novartis

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2S

Salient Pharmaceuticals Incorporated

1 program

Phase 2M

Melinta Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

26 of 28 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody14%Vaccine14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 98% of 54 pipeline programs.

Analysis

Trial Status

66

clinical trials

Completed38 · 58%
Terminated15 · 23%
Unknown status7 · 11%
Withdrawn4 · 6%
Active, not recruiting1 · 2%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

66 trials

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02269150·59 enrolled
A Phase 1 Trial to Evaluate an Orally Ingested Probiotic Yeast Genetically Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
Not yet recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07649096·86 enrolled
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03182907·148 enrolled
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
Completed·Astellas logoAstellas·Phase 4·NCT02254967·364 enrolled
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Completed·Novartis logoNovartis·Phase 2·NCT01232595·109 enrolled
Treatment of Recurrent Clostridium Difficile Infection With RBX7455
Completed·MMayo Clinic·Phase 1·NCT02981316·30 enrolled
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Completed·—·Phase 2·NCT03497806·132 enrolled
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Completed·—·Phase 2·NCT03427229·58 enrolled
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03880539·4 enrolled
Host Immune Response to Clostridium Difficile Infection (ICD)
Completed·HHospices Civils de Lyon·N/A·NCT02440438·56 enrolled
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
Completed·RRebiotix Inc.·Phase 2·NCT02299570·150 enrolled
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Completed·SSummit Therapeutics·Phase 3·NCT03595553·759 enrolled
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Completed·Astellas logoAstellas·Phase 4·NCT02437591·25 enrolled
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
Completed·RRebiotix Inc.·Phase 3·NCT03244644·320 enrolled
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Completed·—·Phase 3·NCT00304356·22 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)